HIGHLIGHTS
- who: Alfonso Ló from the Institut Recerca Biomu00e8dica August Pi i Sunyer (IDIBAPS), Spain University of Virginia, United States have published the article: Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor, in the Journal: (JOURNAL)
SUMMARY
Endocrine therapies (ET) plus targeted-therapies including CDK4/6-inhibitors, PI3K/AKT/mTOR inhibitors have dramatically improved the long-term outcomes in patients with hormone_receptor-positive (HR+), human epidermal growth factor 2negative (HER2-) advanced breast cancer (BC). The frequency of genomic alterations . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.